OKYO Pharma (NASDAQ:OKYO) Stock Breaks Below Fifty Day Moving Average – Here’s Why

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)’s stock price crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $1.42 and traded as low as $1.28. OKYO Pharma shares last traded at $1.28, with a volume of 118,582 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on OKYO. HC Wainwright reiterated a “buy” rating on shares of OKYO Pharma in a research note on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, October 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, OKYO Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $5.67.

OKYO Pharma Stock Down 10.5%

The stock has a fifty day simple moving average of $1.42 and a two-hundred day simple moving average of $1.60.

Institutional Trading of OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Opaleye Management Inc. bought a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 375,204 shares of the company’s stock, valued at approximately $563,000. Opaleye Management Inc. owned approximately 0.71% of OKYO Pharma at the end of the most recent quarter. Institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for inflammatory, ocular and pain-related diseases. The company’s research is centered on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in regulating immune responses, pain signaling and other disease processes.

OKYO’s lead development program, OK-101, is a novel GPCR-targeting therapeutic being investigated for conditions including dry eye disease and neuropathic pain.